id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
94,,,,,,,,,,,,,,,2024-05-11T13:26:00+06:00,BSH - H12303332108,Left,Pacli + Carbo + Trastuzumab + Partuzumab,2023-03-07,4.0,"Started taking Inj.Zoledronic Acid 4mg monthly. Started from 07.12.2020, @India
Started taking Chemotherapy + Antibody therapy with Pertuzumab + Trastuzumab + Docetaxel from
december 2020, completed 6 cycles on 06.04.2021. @India
Started Maintenance antibody therapy with Pertuzumab + Trastuzumab from April 2021. She recived 25th
cycle of maintenance therapy with Pertuzumab + 31st dose of antibody therapy with Trastuzumab. @India
She was started CDK 4/6 inhibitor + HT with Ribociclib + Letrozole from Oct 2021 till Sep 2022 then started
(As pt could not afford Ribo) Fulvestrant + Letroz from September 2022 till March 2023 @India
She completed 4 dose of Lupride 22.5mg q3w on 10.02.2023, 8 doses of Fulvastant 500mg q4w on
9.02.2023, 6 doses of Denosumab 120mg on 18.02.2023. @India
Due to PD she is planned for Pacli + Carbo + Trastuzumab + Partuzumab C1 started from india on
7.03.2023 & C4 completed on 9.05.2023> PD on evaluation on June 24 @Inida> Post Pal RT to brain
and bones
Now on Tab Letrozole & Denosumab 120mg, C9 due on 10.08.2023",2023-06-02,,2023-08-10,,2023-06-02,,,Breast,90,,BSBSC-240000090,SHAMIMA AKTER LOVELY,1672602804,1975-03-02,Female,,,,,Dr Md Arifur Rahman,BSH,2.0,2nd Line,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,C50.4- Upper-outer quadrant of breast,Breast,Left,,,Progressed,Alive,PD,,,,,,,,,,,,,,,,,,,,,
